{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:13:26Z","timestamp":1791090806056,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T00:00:00Z","timestamp":1367884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00280-013-2172-3","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T06:38:56Z","timestamp":1367822336000},"page":"93-100","source":"Crossref","is-referenced-by-count":17,"title":["Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model"],"prefix":"10.1007","volume":"72","author":[{"given":"Rachel","family":"Grossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Zadnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursalan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind P.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/era.10.227","volume":"11","author":"MS Ahluwalia","year":"2011","unstructured":"Ahluwalia MS (2011) 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies. Expert Rev Anticancer Ther 11:161\u2013163","journal-title":"Expert Rev Anticancer Ther"},{"key":"2172_CR2","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1245\/s10434-008-0048-2","volume":"15","author":"FJ Attenello","year":"2008","unstructured":"Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887\u20132893","journal-title":"Ann Surg Oncol"},{"key":"2172_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83\u201395","journal-title":"Cancer Cell"},{"key":"2172_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-008-9678-2","volume":"91","author":"JO Blakeley","year":"2009","unstructured":"Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG, New Approaches to Brain Tumor Therapy Consortium (NABTT) (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51\u201358","journal-title":"J Neurooncol"},{"key":"2172_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0024-3205(90)90043-Q","volume":"46","author":"PM Bungay","year":"1990","unstructured":"Bungay PM, Morrison PF, Dedrick RL (1990) Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci 46:105\u2013119","journal-title":"Life Sci"},{"key":"2172_CR6","doi-asserted-by":"crossref","first-page":"e17228","DOI":"10.1371\/journal.pone.0017228","volume":"6","author":"CT Farrar","year":"2011","unstructured":"Farrar CT, Kamoun WS, Ley CD, Kim YR, Catana C, Kwon SJ, Rosen BR, Jain RK, Sorensen AG (2011) Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS ONE 6:e17228","journal-title":"PLoS ONE"},{"key":"2172_CR7","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"2172_CR8","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"MPD Gibaldi","year":"1982","unstructured":"Gibaldi MPD (1982) Pharmacokinetics. Dekker, New York"},{"key":"2172_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-012-1867-1","volume":"70","author":"R Grossman","year":"2012","unstructured":"Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO (2012) The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol 70:129\u2013139","journal-title":"Cancer Chemother Pharmacol"},{"key":"2172_CR10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-009-1085-7","volume":"65","author":"S Jacobs","year":"2010","unstructured":"Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E (2010) Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 65:817\u2013824","journal-title":"Cancer Chemother Pharmacol"},{"key":"2172_CR11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2008.19.9356","volume":"27","author":"WS Kamoun","year":"2009","unstructured":"Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542\u20132552","journal-title":"J Clin Oncol"},{"key":"2172_CR12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-05-1793","volume":"12","author":"KJ Kim","year":"2006","unstructured":"Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Laterra J (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12:1292\u20131298","journal-title":"Clin Cancer Res"},{"key":"2172_CR13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"2172_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/1056-8719(94)00049-A","volume":"33","author":"A Quellec Le","year":"1995","unstructured":"Le Quellec A, Dupin S, Genissel P, Saivin S, Marchand B, Houin G (1995) Microdialysis probes calibration: gradient and tissue dependent changes in no net flux and reverse dialysis methods. J Pharmacol Toxicol Methods 33:11\u201316","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2172_CR15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/jpet.102.048587","volume":"305","author":"J Ma","year":"2003","unstructured":"Ma J, Li S, Reed K, Guo P, Gallo JM (2003) Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 305:833\u2013839","journal-title":"J Pharmacol Exp Ther"},{"key":"2172_CR16","first-page":"5491","volume":"61","author":"J Ma","year":"2001","unstructured":"Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM (2001) Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 61:5491\u20135498","journal-title":"Cancer Res"},{"key":"2172_CR17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/2008.5.17557","volume":"110","author":"MJ McGirt","year":"2009","unstructured":"McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quinones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583\u2013588","journal-title":"J Neurosurg"},{"key":"2172_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/wnan.17","volume":"1","author":"AP Pathak","year":"2009","unstructured":"Pathak AP (2009) Magnetic resonance susceptibility based perfusion imaging of tumors using iron oxide nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:84\u201397","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2172_CR19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10456-008-9119-z","volume":"11","author":"AP Pathak","year":"2008","unstructured":"Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:321\u2013335","journal-title":"Angiogenesis"},{"key":"2172_CR20","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","volume":"15","author":"J Portnow","year":"2009","unstructured":"Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:7092\u20137098","journal-title":"Clin Cancer Res"},{"key":"2172_CR21","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","volume":"69","author":"AG Sorensen","year":"2009","unstructured":"Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296\u20135300","journal-title":"Cancer Res"},{"key":"2172_CR22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"2172_CR23","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","volume":"65","author":"SR Wedge","year":"2005","unstructured":"Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389\u20134400","journal-title":"Cancer Res"},{"key":"2172_CR24","doi-asserted-by":"crossref","first-page":"E659","DOI":"10.1208\/aapsj070366","volume":"7","author":"Q Zhou","year":"2005","unstructured":"Zhou Q, Gallo JM (2005) In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J 7:E659\u2013E667","journal-title":"AAPS J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2172-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2172-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2172-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T04:00:53Z","timestamp":1644984053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2172-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2172-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,7]]}}}